These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 3054127)

  • 21. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of correctly timing cancer immunotherapy.
    Beyranvand Nejad E; Welters MJ; Arens R; van der Burg SH
    Expert Opin Biol Ther; 2017 Jan; 17(1):87-103. PubMed ID: 27802061
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
    Hekmatshoar Y; Rahbar Saadat Y; Hosseiniyan Khatibi SM; Ozkan T; Zununi Vahed F; Nariman-Saleh-Fam Z; Pourghassem Gargari B; Sunguroglu A; Zununi Vahed S
    Life Sci; 2019 Sep; 233():116680. PubMed ID: 31344431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
    Robert L; Ribas A; Hu-Lieskovan S
    Semin Immunol; 2016 Feb; 28(1):73-80. PubMed ID: 26861544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemoimmunotherapy of solid tumours: improving vaccines?
    Nowak AK; Lake RA; Robinson BW
    Adv Drug Deliv Rev; 2006 Oct; 58(8):975-90. PubMed ID: 17005292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of biomodulators to potentiate chemotherapy in the treatment of cancer.
    Mitchell MS
    Cancer Invest; 1990; 8(2):279-80. PubMed ID: 2400947
    [No Abstract]   [Full Text] [Related]  

  • 27. [The interplay of immunotherapy and chemotherapy, a novel approach].
    Hanoteau A; Henin C; Moser M
    Med Sci (Paris); 2016 Apr; 32(4):353-61. PubMed ID: 27137692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bases on timing of combined modality of chemotherapy and immunotherapy].
    Ogura T
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1414-20. PubMed ID: 1697153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The outlook for combining antitumor and activation therapies].
    Garkavi LKh; Kvakina EB
    Vopr Onkol; 1995; 41(2):47-8. PubMed ID: 7483432
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting A2 adenosine receptors in cancer.
    Allard D; Turcotte M; Stagg J
    Immunol Cell Biol; 2017 Apr; 95(4):333-339. PubMed ID: 28174424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy and chemotherapy--a practical partnership.
    Lake RA; Robinson BW
    Nat Rev Cancer; 2005 May; 5(5):397-405. PubMed ID: 15864281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?
    Perez-Gracia JL; Berraondo P; Martinez-Forero I; Alfaro C; Suarez N; Gurpide A; Sangro B; Hervas-Stubbs S; Ochoa C; Melero JA; Melero I
    Immunotherapy; 2009 Sep; 1(5):845-53. PubMed ID: 20636027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On combining antineoplastic drugs with tumor vaccines.
    Terando A; Mulé JJ
    Cancer Immunol Immunother; 2003 Nov; 52(11):680-5. PubMed ID: 12955481
    [No Abstract]   [Full Text] [Related]  

  • 36. Combinational strategy for high-performance cancer chemotherapy.
    Qin SY; Cheng YJ; Lei Q; Zhang AQ; Zhang XZ
    Biomaterials; 2018 Jul; 171():178-197. PubMed ID: 29698868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
    Terranova-Barberio M; Thomas S; Munster PN
    Immunotherapy; 2016 Jun; 8(6):705-19. PubMed ID: 27197539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy.
    Nars MS; Kaneno R
    Int J Cancer; 2013 Jun; 132(11):2471-8. PubMed ID: 22927096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The heterogeneity of the interaction between cancer chemotherapeutic agents and host resistance mechanisms.
    Spreafico F
    Recent Results Cancer Res; 1980; 75():200-6. PubMed ID: 6453410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.